2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2122

CD38 over-Expression in CD8 Positive Cells Defines a Group of Patients with SLE Prone to Infections
Abstract Number: 2120

CD47- Signal Regulatory Protein Alpha Interaction Potentiates Proinflammatory Response in Systemic Lupus Erythematosus
Abstract Number: 29

CD70-Mediated CD27 Downregulation Contributed to Regulatory B10 Cell Impairment in Rheumatoid Arthritis
Abstract Number: 1090

Cell-Free Mitochondrial DNA As a Novel Biomarker in Systemic Lupus Erythematosus
Abstract Number: 966

Central Triage Clinic for Psoriatic Arthritis – Performance of Triage Methods
Abstract Number: 1765

Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis
Abstract Number: 779

Cerebrospinal Fluid Biomarkers for Diagnosing Neuropsychiatric SLE: A Systematic Review and Meta-Analysis
Abstract Number: 2610

Certolizumab Pegol Serum Levels ≥20 Mg/L Are Associated with Treatment Response in Patients with Axial Spondyloarthritis
Abstract Number: 284

Challenges and Barriers to Employment That Persons with Osteoarthritis Face at Work Due to Their Condition
Abstract Number: 2513

Change in Disease Activity after Switching Etanercept (originator) to Biosimilar (Benepali) Is Associated with Active Disease at Baseline
Abstract Number: 2175

Change in Frequency of Arthroplasty Surgery in Rheumatoid Arthritis: A 13-Year Population Health Study
Abstract Number: 568

Change in RF and Anti-CCP Isotype Levels in RA Patients Treated with Anti-TNF, Abatacept, Rituximab or Tocilizumab and Correlation with Clinical and Radiographic Outcomes: Data from a Randomized Trial
Abstract Number: 210

Changes in Alcohol Use in Patients with Rheumatoid Arthritis: Associations with Disease Activity, Health Status, and Mortality
Abstract Number: 2662

Changes in Blood Pressure and Proteinuria at One Year in Two Lupus Nephritis Clinical Trials
Abstract Number: 584

Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].